CoChat

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

Open access
Landmesser, Ulf, McGinniss, Jennifer, Steg, Ph Gabriel, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Dilic, Mirza, Goodman, Shaun G, Jukema, J Wouter, Loy, Megan, Pećin, Ivan, Pordy, Robert, Poulsen, Steen H, Szarek, Michael, White, Harvey D, Schwartz, Gregory G, for the ODYSSEY OUTCOMES Investigators · 2022 · European Journal of Preventive Cardiology
Cited by 17

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims: European guidelines set low-density lipoprotein cholesterol (LDL-C) treatment goals <1.4 mmol/L after acute coronary syndrome (ACS), and <1.0 mmol/L for patients with recurrent cardiovascular events ≤2 years. Many ACS patients do not achieve these goals on statin alone. We examined actual goal achievement with alirocumab and projected achievement with ezetimibe, either added to optimized statin therapy. Methods and results: The ODYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18 924 patients with recent ACS and hyperlipidaemia despite high-intensity or maximum-tolerated statin therapy. This subanalysis comprised 17 589 patients with LDL-C ≥1.4 mmol/L at baseline who did not receive ezetimibe treatment. High-intensity statin treatment was used in 88.8%. Median (interquartile range) baseline LDL-C was 2.3 (1.9−2.7) mmol/L. With alirocumab, 94.6% of patients achieved LDL-C <1.4 mmol/L at ≥1 post-baseline measurement vs. 17.3% with placebo. Among 2236 patients with a previous cardiovascular event within 2 years (before the qualifying ACS), 85.2% vs. 3.5%, respectively, achieved LDL-C <1.0 mmol/L. Among patients not treated with ezetimibe, we projected that its use would have achieved LDL-C <1.4 and <1.0 mmol/L in 10.6 and 0%, respectively, at baseline (assuming 18 ± 3% reduction of LDL-C). Conclusion: Among patients with recent ACS and LDL-C ≥1.4 mmol/L despite optimized statin therapy, the addition of alirocumab allowed 94.6% to achieve the 2019 European guideline LDL-C goal <1.4 mmol/L, and 85.2% of those with recurrent cardiovascular events to achieve <1.0 mmol/L. In contrast, the addition of ezetimibe to optimized statin therapy was projected to achieve LDL-C <1.4 mmol/L in only 10.6% of patients at baseline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjpc/zwac107

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 17

Metadata

Authors
Landmesser, U., McGinniss, J., Steg, P. G., Bhatt, D. L., Bittner, V. A., Diaz, R., Dilic, M., Goodman, S. G., Jukema, J. W., Loy, M., Pećin, I., Pordy, R., Poulsen, S. H., Szarek, M., White, H. D., Schwartz, G. G., & for the ODYSSEY OUTCOMES Investigators
Venue
European Journal of Preventive Cardiology
Published
2022-06-16
Volume
29
Issue
14
Pages
1842-1851
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W4282966850
Cited by
17
References
7
FWCI
3.18
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. https://app.cochat.ai/papers/10.1093/eurjpc/zwac107
The paper
Landmesser, U., McGinniss, J., Steg, P. G., Bhatt, D. L., Bittner, V. A., Diaz, R., Dilic, M., Goodman, S. G., Jukema, J. W., Loy, M., Pećin, I., Pordy, R., Poulsen, S. H., Szarek, M., White, H. D., Schwartz, G. G., & for the ODYSSEY OUTCOMES Investigators. (2022). Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwac107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.